According to an preliminary study published on Wednesday in Journal Nature, an individual MRNA vaccine may reduce the risk of pancreatic cancer returning after surgery.
Pancreatic cancer is one of the most aggressive cancer, which according to the study is only one year of specific survival rate after about one year after diagnosis.
While the conclusions are encouraging, the vaccine is still in the initial test and it will probably take it in the years before it is widely available – assuming that success in ongoing tests continues to show, Dr. Vinod p. According to Balachandran, the lead investigator and senior writers of the test. of study.
In this small, initial test of 16 patients, half had a strong immune response to the vaccine. Most of these respondents remained cancer-free for more than three years, longer than those who did not respond.
Vaccine is known as T cells to identify and attack cancer, special immune system works by training cells.
In Thi Sundated Stock Photo, a medical professional is seen holding the Covid-19 vaccine.
Stock Photo/Adobe Stock
Researchers could not track tumor shrinkage as all patients had surgery to remove visual cancer before vaccination. However, he found that the vaccine produced long -lasting T cells that could continue to fight cancer for years.
“This is a way through which you can make a lot of T cells, and you can make these T cells so that they can remain longer in patients and maintain their work,” Balachandran said.
Balachandran said that “being able to obtain immune response has been very challenging,” especially when diseases like pancreatic cancer usually do not respond to vaccines, which highlights the importance of these conclusions.
A major test is now underway to confirm the results. When successful, this approach can create new ways to prevent or prevent pancreatic and other advanced cancer.
Overall, Balachandran said that this study “can provide some important clues how you will be able to develop vaccines more widely for other cancers.”
“Hopefully this information that we will learn from these clinical trials will give us information to implement the vaccine in other settings, such as primary prevention, which means preventing cancer before occurring, vaccine Along with or perhaps its use is also a more advanced disease to treat those patients, “Balachandran said.
-Suhs Kocht, MD, contributed to this report
